Neuroendocrine Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
Clin Endocrinol (Oxf). 2012 Jul;77(1):86-93. doi: 10.1111/j.1365-2265.2011.04303.x.
Prader-Willi syndrome (PWS) is associated with GH deficiency, deleterious changes in body composition and function. As the effects of recombinant human GH (rhGH) in PWS adults have not been well established, we sought to conduct a meta-analysis of pertinent studies.
Meta-analysis of studies examining the effects of rhGH therapy in PWS adults.
One hundred and thirty four PWS adults (75 men, 59 women).
Literature searches, including publications (PubMed, EMBASE and the Cochrane Register), and abstracts presented at meetings through July 2011 describing studies of rhGH therapy in PWS adults; 8/1194 articles, describing unique cohorts, were included. Two authors independently extracted data and examined study quality.
rhGH therapy for 12 months led to [weighted mean difference (95% CI)] decreased body fat [-2·91% (-3·90, -1·91)], visceral [-32·97 cm(2) (-55·67, -10·26)] and subcutaneous adiposity [-55·24 cm(2) (-89·05, -21·44)], and increased lean body mass (LBM) [2·41 Kg (1·32, 3·49)]. Similar changes in body fat [-2·89% (-4·69, -1·07)] and LBM [2·82 Kg (1·31, 4·33)] were found in longer studies. There were no changes in body mass index (BMI) or lipids. There was a small increase in fasting glucose [0·27 mmol/l (0·05, 0·49)] and trends towards higher fasting insulin [20·24 pmol/l (-0·55, 41·02)] and insulin resistance [HOMA: 0·60 (-0·04, 1·24)] after rhGH therapy for 12 months.
In PWS adults, rhGH therapy led to decreased body adiposity and increased LBM without changes in BMI or lipids. There was a small increase in fasting glucose and trends towards higher insulin and insulin resistance.
普拉德-威利综合征（PWS）与生长激素缺乏症、身体成分和功能的有害变化有关。由于重组人生长激素（rhGH）在 PWS 成人中的作用尚未得到充分证实，我们试图对相关研究进行荟萃分析。
对研究 rhGH 治疗 PWS 成人的影响的荟萃分析。
134 名 PWS 成人（75 名男性，59 名女性）。
文献检索，包括出版物（PubMed、EMBASE 和 Cochrane 注册）和 2011 年 7 月前会议上的摘要，描述了 rhGH 治疗 PWS 成人的研究；包括 8/1194 篇描述独特队列的文章。两位作者独立提取数据并检查研究质量。
rhGH 治疗 12 个月导致[加权平均差异（95%CI）]体脂减少[-2.91%（-3.90，-1.91）]，内脏[-32.97cm²（-55.67，-10.26）]和皮下脂肪[-55.24cm²（-89.05，-21.44）]，以及增加瘦体重（LBM）[2.41kg（1.32，3.49）]。在更长时间的研究中，也发现了体脂[2.89%（-4.69，-1.07）]和 LBM [2.82kg（1.31，4.33）]的类似变化。BMI 或血脂没有变化。rhGH 治疗 12 个月后，空腹血糖[0.27mmol/L（0.05，0.49）]略有升高，空腹胰岛素[20.24pmol/L（-0.55，41.02）]和胰岛素抵抗[HOMA：0.60（-0.04，1.24）]呈升高趋势。
在 PWS 成人中，rhGH 治疗导致体脂减少和 LBM 增加，而 BMI 或血脂没有变化。空腹血糖略有升高，胰岛素和胰岛素抵抗呈升高趋势。
